Intrinsic and tumor microenvironment-induced metabolism adaptations of T cells and impact on their differentiation and function

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Kouidhi, Soumaya ^a,b   Noman, Muhammad Zaeem ^c   Kieda, Claudine ^d   Elgaaied, Amel Benammar ^b   Chouaib, Salem ^c  

^a Biotechpole Sidi Thabet   (Tunisia)

^b FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^c INSERM   (France)

^d CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

Cancer; Hypoxia; Immune system; T lymphocytes; Tumor cell metabolism; Tumor microenvironment

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 17; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE C; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR;

BROWN ADIPOSE TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELLULAR IMMUNITY; GLUCOSE METABOLISM; GLYCOLYSIS; HYPOXIA; INFLAMMATION; LIPID OXIDATION; NATURAL KILLER T CELL; OBESITY; OXIDATIVE PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH17 CELL; TUMOR MICROENVIRONMENT;

EID: 84964665975     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00114     Document Type: Review

References (125)

1. Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe (2014) 15:295-305. doi:10.1016/j.chom.2014.02.003.
2. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol (2013) 31:259-83. doi:10.1146/annurev-immunol-032712-095956.
3. Mathis D, Shoelson SE. Immunometabolism: an emerging frontier. Nat Rev Immunol (2011) 11:81. doi:10.1038/nri2922.
4. Coe DJ, Kishore M, Marelli-Berg F. Metabolic regulation of regulatory T cell development and function. Front Immunol (2014) 5:590. doi:10.3389/fimmu.2014.00590.
5. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab (2014) 20:61-72. doi:10.1016/j.cmet.2014.05.004.
6. Ramsay G, Cantrell D. Environmental and metabolic sensors that control T cell biology. Front Immunol (2015) 6:99. doi:10.3389/fimmu.2015.00099.
7. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 123:3664-71. doi:10.1172/JCI67230.
8. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, et al. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol (2015) 309:C569-79. doi:10.1152/ajpcell.00207.2015.
9. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res (2014) 74:665-74. doi:10.1158/0008-5472.CAN-13-0992.
10. Labiano S, Palazon A, Melero I. Immune response regulation in the tumor microenvironment by hypoxia. Semin Oncol (2015) 42:378-86. doi:10.1053/j.seminoncol.2015.02.009.
11. Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity (2015) 43:435-49. doi:10.1016/j.immuni.2015.09.001.
12. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature (2013) 493:346-55. doi:10.1038/nature11862.
13. Norata GD, Caligiuri G, Chavakis T, Matarese G, Netea MG, Nicoletti A, et al. The cellular and molecular basis of translational immunometabolism. Immunity (2015) 43:421-34. doi:10.1016/j.immuni.2015.08.023.
14. Iyer A, Brown L, Whitehead JP, Prins JB, Fairlie DP. Nutrient and immune sensing are obligate pathways in metabolism, immunity, and disease. FASEB J (2015) 29:3612-25. doi:10.1096/fj.15-271155.
15. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc (2011) 70:408-17. doi:10.1017/S0029665111000565.
16. Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol (2014) 382:570-82. doi:10.1016/j.mce.2013.03.025.
17. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 342:1242454. doi:10.1126/science.1242454.
18. Guppy M, Greiner E, Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem (1993) 212:95-9. doi:10.1111/j.1432-1033.1993.tb17637.x.
19. Marelli-Berg FM, Fu H, Mauro C. Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. Immunology (2012) 136:363-9. doi:10.1111/j.1365-2567.2012.03583.x.
20. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol (2010) 185:1037-44. doi:10.4049/jimmunol.0903586.
21. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 180:4476-86. doi:10.4049/jimmunol.180.7.4476.
22. Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW Jr, Glick GD. Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation. Immunol Rev (2012) 249:104-15. doi:10.1111/j.1600-065X.2012.01148.x.
23. Ron-Harel N, Sharpe AH, Haigis MC. Mitochondrial metabolism in T cell activation and senescence: a mini-review. Gerontology (2015) 61:131-8. doi:10.1159/000362502.
24. Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol (2007) 178:2163-70. doi:10.4049/jimmunol.178.4.2163.
25. Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD. Anergic T cells are metabolically anergic. J Immunol (2009) 183:6095-101. doi:10.4049/jimmunol.0803510.
26. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol (2012) 13:907-15. doi:10.1038/ni.2386.
27. Yaqoob P, Calder PC. Glutamine requirement of proliferating T lymphocytes. Nutrition (1997) 13, 646-651.
28. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 27:441-64. doi:10.1146/annurev-cellbio-092910-154237.
29. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med (2015) 212:1345-60. doi:10.1084/jem.20151159.
30. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 13:227-42. doi:10.1038/nri3405.
31. Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol (2004) 172:4661-5. doi:10.4049/jimmunol.172.8.4661.
32. Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IkappaB kinase alpha (IKKalpha). J Biol Chem (2014) 289:25227-40. doi:10.1074/jbc. M114.554881.
33. Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle (2015) 14:473-80. doi:10.4161/15384101.2014.991572.
34. Delgoffe GM, Powell JD. mTOR: taking cues from the immune microenvironment. Immunology (2009) 127:459-65. doi:10.1111/j.1365-2567.2009.03125.x.
35. Peter C, Waldmann H, Cobbold SP. mTOR signalling and metabolic regulation of T cell differentiation. Curr Opin Immunol (2010) 22:655-61. doi:10.1016/j.coi.2010.08.010.
36. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 33:301-11. doi:10.1016/j.immuni.2010.09.002.
37. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208:1367-76. doi:10.1084/jem.20110278.
38. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146:772-84. doi:10.1016/j.cell.2011.07.033.
39. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A (2012) 109:E2784-93. doi:10.1073/pnas.1202366109.
40. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell (2010) 140:883-99. doi:10.1016/j.cell.2010.01.025.
41. Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD. Special conference on tumor immunology and immunotherapy: a new chapter. Cancer Immunol Res (2015) 3(6):1-8. doi:10.1158/2326-6066.CIR-15-0106.
42. Miura G. Tumor immunology: assembling the T cell. Nat Chem Biol (2015) 11:902. doi:10.1038/nchembio.1969.
43. Sautes-Fridman C. Tumor immunology, toward a success story? Front Immunol (2015) 6:65. doi:10.3389/fimmu.2015.00065.
44. Ha TY. The role of regulatory T cells in cancer. Immune Netw (2009) 9:209-35. doi:10.4110/in.2009.9.6.209.
45. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 22:327-34. doi:10.1016/j.semcancer.2012.03.004.
46. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, et al. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol (2010) 28:79-105. doi:10.1146/annurev-immunol-030409-101308.
47. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 6:6692. doi:10.1038/ncomms7692.
48. O'Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol (2015) 36:71-80. doi:10.1016/j.it.2014.12.004.
49. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res (2015) 4:560-75. doi:10.3978/j.issn.2218-6751.2015.06.06.
50. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
51. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 21:297-308. doi:10.1016/j.ccr.2012.02.014.
52. Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med (2014) 11:1-19. doi:10.7497/j.issn.2095-3941.2014.01.001.
53. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 8:74-80. doi:10.1038/nri2233.
54. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res (2015) 21:687-92. doi:10.1158/1078-0432.CCR-14-1860.
55. Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res (2014) 74:3205-17. doi:10.1158/0008-5472.CAN-13-3461.
56. Hall A, Meyle KD, Lange MK, Klima M, SanderhoffM, Dahl C, et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 4:584-99. doi:10.18632/oncotarget.965.
57. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell (2013) 23:302-15. doi:10.1016/j.ccr.2013.02.003.
58. Cham CM, Driessens G, O'Keefe JP, Gajewski TF. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol (2008) 38:2438-50. doi:10.1002/eji.200838289.
59. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 109:3812-9. doi:10.1182/blood-2006-07-035972.
60. Nakamura H, Makino Y, Okamoto K, Poellinger L, Ohnuma K, Morimoto C, et al. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J Immunol (2005) 174:7592-9. doi:10.4049/jimmunol.174.12.7592.
61. Lukashev D, Caldwell C, Ohta A, Chen P, Sitkovsky M. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem (2001) 276:48754-63. doi:10.1074/jbc. M104782200.
62. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol (2013) 14:1173-82. doi:10.1038/ni.2714.
63. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 72:2162-71. doi:10.1158/0008-5472.CAN-11-3687.
64. Roman J, Ritzenthaler JD, Roser-Page S, Sun X, Han S. alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol (2010) 43:684-91. doi:10.1165/rcmb.2009-0375OC.
65. Zuckerberg AL, Goldberg LI, Lederman HM. Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit Care Med (1994) 22:197-203. doi:10.1097/00003246-199402000-00008.
66. Carraro F, Pucci A, Pellegrini M, Pelicci PG, Baldari CT, Naldini A. p66Shc is involved in promoting HIF-1alpha accumulation and cell death in hypoxic T cells. J Cell Physiol (2007) 211:439-47. doi:10.1002/jcp.20951.
67. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y, et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol (2003) 171:6534-40. doi:10.4049/jimmunol.171.12.6534.
68. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med (2014) 20:607-15. doi:10.1038/nm.3541.
69. AppelhoffRJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem (2004) 279:38458-65. doi:10.1074/jbc. M406026200.
70. Briken V, Mosser DM. Editorial: switching on arginase in M2 macrophages. J Leukoc Biol (2011) 90:839-41. doi:10.1189/jlb.0411203.
71. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm (2015) 2015:816460. doi:10.1155/2015/816460.
72. Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol (2008) 180:7175-83. doi:10.4049/jimmunol.180.11.7175.
73. Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 122:3062-73. doi:10.1182/blood-2013-05-500801.
74. Tkachev V, Goodell S, Opipari AW, Hao LY, Franchi L, Glick GD, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol (2015) 194:5789-800. doi:10.4049/jimmunol.1402180.
75. He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep (2015) 5:13110. doi:10.1038/srep13110.
76. Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol (2011) 76:325-34. doi:10.1101/sqb.2012.76.010900.
77. Buchheit CL, Rayavarapu RR, Schafer ZT. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Semin Cell Dev Biol (2012) 23:402-11. doi:10.1016/j.semcdb.2012.04.007.
78. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029-33. doi:10.1126/science.1160809.
79. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 11:85-95. doi:10.1038/nrc2981.
80. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget (2010) 1:734-40. doi:10.18632/oncotarget.208.
81. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 2:881-98. doi:10.1158/2159-8290.CD-12-0345.
82. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 27:5497-510. doi:10.1038/onc.2008.245.
83. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 441:424-30. doi:10.1038/nature04869.
84. Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, et al. Signaling through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. J Biol Chem (2015) 290:17495-504. doi:10.1074/jbc. M115.660498.
85. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 39:171-83. doi:10.1016/j.molcel.2010.06.022.
86. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer (2008) 8:705-13. doi:10.1038/nrc2468.
87. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol (2006) 16:253-64. doi:10.1016/j.semcancer.2006.07.014.
88. Wilde BR, Ayer DE. Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis. Br J Cancer (2015) 113:1529-33. doi:10.1038/bjc.2015.360.
89. Dai Q, Yin Y, Liu W, Wei L, Zhou Y, Li Z, et al. Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells. Int J Biochem Cell Biol (2013) 45:1468-78. doi:10.1016/j.biocel.2013.04.015.
90. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci (2014) 15:6184-223. doi:10.3390/ijms15046184.
91. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest (2006) 116:1793-801. doi:10.1172/JCI29069.
92. Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells (2014) 37:365-71. doi:10.14348/molcells.2014.0074.
93. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med (2012) 18:363-74. doi:10.1038/nm.2627.
94. BrestoffJR, Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell (2015) 161:146-60. doi:10.1016/j.cell.2015.02.022.
95. Exley MA, Hand L, O'Shea D, Lynch L. Interplay between the immune system and adipose tissue in obesity. J Endocrinol (2014) 223:R41-8. doi:10.1530/JOE-13-0516.
96. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol (2008) 8:923-34. doi:10.1038/nri2449.
97. Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: all immune cells on the stage. Trends Mol Med (2013) 19:487-500. doi:10.1016/j.molmed.2013.05.001.
98. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007) 117:175-84. doi:10.1172/JCI29881.
99. Ferrante AW Jr. Macrophages, fat, and the emergence of immunometabolism. J Clin Invest (2013) 123:4992-3. doi:10.1172/JCI73658.
100. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity (2014) 41:36-48. doi:10.1016/j.immuni.2014.05.010.
101. Fracchia KM, Walsh CM. Metabolic mysteries of the inflammatory response: T cell polarization and plasticity. Int Rev Immunol (2015) 34:3-18. doi:10.3109/08830185.2014.974748.
102. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med (2009) 15:914-20. doi:10.1038/nm.1964.
103. Morris DL, Cho KW, Delproposto JL, Oatmen KE, Geletka LM, Martinez-Santibanez G, et al. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes (2013) 62:2762-72. doi:10.2337/db12-1404.
104. Schreiber HA, Loschko J, Karssemeijer RA, Escolano A, Meredith MM, Mucida D, et al. Intestinal monocytes and macrophages are required for T cell polarization in response to Citrobacter rodentium. J Exp Med (2013) 210:2025-39. doi:10.1084/jem.20130903.
105. Stolarczyk E, Vong CT, Perucha E, Jackson I, Cawthorne MA, Wargent ET, et al. Improved insulin sensitivity despite increased visceral adiposity in mice deficient for the immune cell transcription factor T-bet. Cell Metab (2013) 17:520-33. doi:10.1016/j.cmet.2013.02.019.
106. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab (2010) 21:345-52. doi:10.1016/j.tem.2010.01.009.
107. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest (2006) 116:3015-25. doi:10.1172/JCI28898.
108. Wagner M, Samdal Steinskog ES, Wiig H. Adipose tissue macrophages: the inflammatory link between obesity and cancer? Expert Opin Ther Targets (2015) 19:527-38. doi:10.1517/14728222.2014.991311.
109. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0.
110. Hefetz-Sela S, Scherer PE. Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther (2013) 138:197-210. doi:10.1016/j.pharmthera.2013.01.008.
111. Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the microenvironment: links to cancer. J Carcinog (2013) 12:19. doi:10.4103/1477-3163.119606.
112. Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective. Cancer Treat Res (2014) 159:21-33. doi:10.1007/978-3-642-38007-5_2.
113. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1825:207-22. doi:10.1016/j.bbcan.2012.01.002.
114. Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol (2012) 8:263-75. doi:10.1038/nrendo.2011.184.
115. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J (1998) 12:57-65.
116. Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev (2010) 29:569-79. doi:10.1007/s10555-010-9247-y.
117. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer (2013) 12:152. doi:10.1186/1476-4598-12-152.
118. Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett (2014) 355:176-83. doi:10.1016/j.canlet.2014.09.003.
119. Strum SB, Adalsteinsson O, Black RR, Segal D, Peress NL, Waldenfels J. Case report: sodium dichloroacetate (DCA) inhibition of the "Warburg effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP. J Bioenerg Biomembr (2013) 45:307-15. doi:10.1007/s10863-012-9496-2.
120. Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell (2014) 5:592-602. doi:10.1007/s13238-014-0082-8.
121. Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis (2014) 3:e103. doi:10.1038/oncsis.2014.18.
122. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 68:7409-18. doi:10.1158/0008-5472.CAN-08-1522.
123. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 9:237-49. doi:10.2174/156800909787580999.
124. O'Regan R, Hawk NN. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets (2011) 15:859-72. doi:10.1517/14728222.2011.575362.
125. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Targeting hypoxic response for cancer therapy. Oncotarget (2016). doi:10.18632/oncotarget.7229.